Clinuvel Pharmaceuticals Limited (CLVLF)
USD 6.95
(-4.79%)
USD 6.95
(-4.79%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 879.78 Thousand AUD | -12.01% |
| 2023 | 999.86 Thousand AUD | -20.43% |
| 2022 | 1.25 Million AUD | -3.6% |
| 2021 | 1.3 Million AUD | -1.22% |
| 2020 | 1.31 Million AUD | 205.09% |
| 2019 | 432.51 Thousand AUD | 0.0% |
| 2018 | - AUD | 0.0% |
| 2017 | - AUD | 0.0% |
| 2016 | - AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| 2006 | - AUD | 0.0% |
| 2005 | - AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 713.05 Thousand AUD | -28.68% |
| 2024 Q2 | 1.06 Million AUD | 49.9% |
| 2024 Q4 | 879.78 Thousand AUD | 0.0% |
| 2024 FY | 879.78 Thousand AUD | -12.01% |
| 2023 Q2 | 1.13 Million AUD | 39.67% |
| 2023 Q3 | 699.02 Thousand AUD | -38.45% |
| 2023 Q1 | 813.12 Thousand AUD | -35.29% |
| 2023 Q4 | 999.86 Thousand AUD | 43.04% |
| 2023 FY | 999.86 Thousand AUD | -20.43% |
| 2022 Q2 | 1.16 Million AUD | 29.58% |
| 2022 Q4 | 1.25 Million AUD | 33.47% |
| 2022 Q1 | 902.69 Thousand AUD | -30.75% |
| 2022 Q3 | 941.46 Thousand AUD | -19.52% |
| 2022 FY | 1.25 Million AUD | -3.6% |
| 2021 FY | 1.3 Million AUD | -1.22% |
| 2021 Q4 | 1.3 Million AUD | 24.71% |
| 2021 Q1 | 1.13 Million AUD | -13.89% |
| 2021 Q3 | 1.04 Million AUD | -23.98% |
| 2021 Q2 | 1.37 Million AUD | 21.0% |
| 2020 Q3 | 1.1 Million AUD | 259.42% |
| 2020 Q2 | 308.05 Thousand AUD | 381.77% |
| 2020 FY | 1.31 Million AUD | 205.09% |
| 2020 Q1 | 63.94 Thousand AUD | -85.22% |
| 2020 Q4 | 1.31 Million AUD | 19.18% |
| 2019 Q4 | 432.51 Thousand AUD | 152.54% |
| 2019 Q1 | - AUD | 0.0% |
| 2019 Q2 | - AUD | 0.0% |
| 2019 Q3 | 171.26 Thousand AUD | 0.0% |
| 2019 FY | 432.51 Thousand AUD | 0.0% |
| 2018 Q3 | - AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 Q1 | - AUD | 0.0% |
| 2018 FY | - AUD | 0.0% |
| 2018 Q2 | - AUD | 0.0% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 FY | - AUD | 0.0% |
| 2017 Q3 | - AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 Q1 | - AUD | 0.0% |
| 2016 FY | - AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 Q3 | - AUD | 0.0% |
| 2016 Q2 | - AUD | 0.0% |
| 2016 Q1 | - AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2015 Q3 | - AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q1 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2006 FY | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2005 Q4 | - AUD | 0.0% |
| 2005 FY | - AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -244.214% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 34.52% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 28.377% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 97.972% |
| GB Sciences, Inc. | 1.75 Million USD | 49.993% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 4.61 Million USD | 80.938% |
| Zenith Capital Corp. | 10.22 Thousand USD | -8504.244% |
| Agentix Corp. | 50 Thousand USD | -1659.568% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 85.015% |
| Biomind Labs Inc. | 735.54 Thousand USD | -19.61% |
| ContraFect Corporation | 2.88 Million USD | 69.463% |
| CSL Limited | 12.18 Billion USD | 99.993% |
| CytoDyn Inc. | 30.07 Million USD | 97.075% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -144.581% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -39.631% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 98.069% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 7.222% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -16.342% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 97.044% |
| SQZ Biotechnologies Company | 27.47 Million USD | 96.797% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 0.932% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 97.865% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 62.175% |
| Mesoblast Limited | 118.7 Million USD | 99.259% |
| Marizyme, Inc. | 18.71 Million USD | 95.3% |
| Genus plc | 233.1 Million USD | 99.623% |
| Pharming Group N.V. | 171.54 Million USD | 99.487% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -17.305% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 39.171% |
| IMV Inc. | 28.88 Million USD | 96.954% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 84.452% |
| MultiCell Technologies, Inc. | 202.58 USD | -434189.663% |
| ONE Bio Corp. | 19.71 Million USD | 95.537% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 98.47% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 97.342% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 70.928% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 93.231% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -521.676% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -3320.755% |
| Alpha Cognition Inc. | 1.22 Million USD | 27.909% |
| Enzolytics Inc. | 996.33 Thousand USD | 11.698% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 95.601% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 87.561% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.789% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 78.656% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -118.934% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 63.308% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -283.698% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -491.833% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 69.977% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -549.349% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 41.142% |
| Q BioMed Inc. | 4.1 Million USD | 78.594% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 95.672% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 98.699% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 81.327% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 61.044% |
| HST Global, Inc. | 98.31 Thousand USD | -794.826% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -253.725% |
| Halberd Corporation | 150 Thousand USD | -486.523% |
| Resverlogix Corp. | 6.49 Million USD | 86.446% |
| Cell Source, Inc. | 9.25 Million USD | 90.493% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 67.52% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -338.541% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | 60.008% |
| Kadimastem Ltd | 891.22 Thousand USD | 1.284% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -317.009% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -251.658% |
| LadRx Corporation | 33.6 Thousand USD | -2517.937% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -16.342% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -285.233% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 82.344% |
| Mobile Lads Corp. | 484.28 Thousand USD | -81.667% |
| International Stem Cell Corporation | 4.17 Million USD | 78.942% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.92 Million USD | 54.297% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -150.047% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 88.75% |
| SYBLEU INC | 477.5 Thousand USD | -84.248% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -618.191% |
| Rebus Holdings, Inc. | 310 Thousand USD | -183.801% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 81.421% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1309.617% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 59.66% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 89.421% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 89.752% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 43.44% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -228.278% |
| Neutra Corp. | 54.15 Thousand USD | -1524.537% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 51.924% |
| PureTech Health plc | 25.51 Million USD | 96.551% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 28.135% |
| IXICO plc | 472.02 Thousand USD | -86.386% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 94.324% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.587% |
| CSL Limited | 12.18 Billion USD | 99.993% |
| Cellectis S.A. | 92.77 Million USD | 99.052% |